IRIDEX Corp (IRIX) stock

IRIXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends January 3

Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 18, 2026Score 8/30

$0.69−0.02 (-2.75%)

Close on Nov 13, 2026Market cap $12.12MP/E –Yield –

Iridex EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Iridex's EV/EBITDA was 132.0× on Oct 31, 2016, against 39.8× a year earlier. Over the last 5 years it ranged from 9.2× to 262.6×, with a median of 28.4×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2016	Oct 31, 2016	132.0×	+68.1
2015	Dec 31, 2015	63.9×	+36.3
2014	Dec 31, 2014	27.6×	−2.3
2013	Dec 31, 2013	30.0×	−9.3
2012	Dec 31, 2012	39.2×	−20.1
2011	Dec 30, 2011	59.3×	+41.0
2010	Dec 31, 2010	18.3×	–

Where these numbers come from

Parsed from the XBRL in Iridex's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IRIX.

Compare: IRIX vs SGHT · IRIX vs FOCL · IRIX vs LNSR · IRIX vs ESMC · IRIX vs ELMD

Revenue growth3.7% · median 9.9%

Gross margin35.9% · median 65.5%

Operating margin-5.4% · median -1.5%

Net margin-6.9% · median 23.6%

Company	Revenue	Growth
SGHT	$88.39M	+16.2%
ELMD	$75.57M	+14.1%
LNSR	$60.08M	+1.6%
IRIX	$51.57M	+3.7%
ESMC	$12.74M	+5.7%
FOCL	–	–

Company

Exchange: Nasdaq
Industry: Electromedical & Electrotherapeutic Apparatus
Fiscal year ends: January 3
Employees: 93
Held by institutions: 12.4%
Auditor: BPM LLP
SEC CIK: 1006045

Advertisement
300 × 250

See a number that looks wrong?